All News

@RheumNow #acr20 abs1306 CBP highly prevalent in anterior uveitis. 53%of uveitis pts complain of CBP. 23% eventually diagnosed/meet Dx criteria for AxPsA. 87%had already had CBP w/ previous episodes of uveitis. Men more likely to be clinically diagnosed ( 33%M vs13%F). https://t.co/2y0NxJOFRp
Olga Petryna DrPetryna ( View Tweet)
So excited to check out RheumNow’s ACR Mid-Meeting Recap live right now with Dr. Jack Cush (@rheumnow), Dr. Arthur Kavanaugh, Dr. Michale Pillinger, and Dr. Bella Mehta! #ACR20

Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)

Ultrasound to assess synovial-entheses junction correlated with clinical findings Abs#0311 Do you use MSK US in your clinic? @RheumNow #ACR20

Robert B Chao, MD doctorRBC ( View Tweet)

@RheumNow #acr20 abs0876 gender differences AS and nrSpA from 3 RCT IXE trials: F more likely to be older, have more nocturnal BP, peripheral pain&fatigue. M have higher CRP & +HLAB27. Ant uveitis > in M w/AS (23.8% vs. 17.9%) but > common in F w/ nr-axSpA (15.2% vs. 7.1%). https://t.co/HZa7AfWbBh

Olga Petryna DrPetryna ( View Tweet)
RheumNow’s expanded coverage of the #ACR20 Annual meeting is sponsored in part by @Novartis. All content chosen by RheumNow + its Faculty.

Dr. John Cush RheumNow ( View Tweet)

Are SpA response differences part of disease subsets or drug pharmacodynamics or both or neither? Data from COASTW & MEASURE2 @RheumNow #ACR2020 @CRASCRRheum https://t.co/GsFjZuZRvI

Links:

Janet Pope Janetbirdope ( View Tweet)

Dr. Jonathan Kay with changes in ICD coding from ICD-9 to ICD-10. And we just got an ICD code for nr-axSpA! It's M46.80 https://t.co/JAlF4ERoHr #ACR20 https://t.co/lmElQVtv35

Links:

Rheum Cat rheum_cat ( View Tweet)
Dr. M. Dubreuil shares a beautiful slide describing the asynchrony between the goal and the reality in the classification of axSpA. Do you think it’s time to change our nomenclature and classification criteria? #ACR20 @RheumNow https://t.co/YJcvLKnyFy
Dr. Rachel Tate uptoTate ( View Tweet)
Dr. J. Kay reviews ICD11 classification codes for medical claims for diagnosing SpA which reviews ASAS criteria. This likely won’t be adopted in the US for several years. #ACR20 ⁦@RheumNow⁩ https://t.co/oDhs1EHSTP
Dr. Rachel Tate uptoTate ( View Tweet)
Do you know Walter Bauer, MD #ACR20? Well, I didn't either! Dr. M. Weinblatt taught me that Dr. Bauer was an important US rheumatologist who did NOT believe AS was a separate disease entity from RA! It wasn't until his death that the college recognized both separately! @RheumNow

Dr. Rachel Tate uptoTate ( View Tweet)

Listen to part I of our #ACR20 Day 1 recap. Listen through the link below or find us on Apple podcasts. https://t.co/W6EMQiF9Rf https://t.co/R1ieCFnIxz

Links:

Dr. John Cush RheumNow ( View Tweet)

Gender differences in Axial Spondyloarthritis patients Pooled data from 3 Ixekizumab studies Women: 1⃣older at disease onset (30 vs. 26) 2⃣Longer symptom duration (17.8 yrs vs. 16.7 yrs) 3⃣More peripheral joint pain and lower HLA-B27 @RheumNow #ACR20 Abs#0876 https://t.co/qGHXApi0Ko

Robert B Chao, MD doctorRBC ( View Tweet)

Another biosimilar Adalimumab. SB5 switch in RA, PsA & SpA N=354 No diff in effectiveness Some minor flares. Some changed dose unsure why. #ACR2020 @RheumNow @CRASCRRheum abstr#805 https://t.co/2Zb4H2jBXQ

Janet Pope Janetbirdope ( View Tweet)
MEASURE2 and COAST-W data stratified by TNFi inadequate responders may suggest different axSpA subset (domain?) response to TNFi vs IL17i. Dr. J. Ermann #ACR20 @RheumNow #ACRbest https://t.co/0ZcEIvkuMj
Dr. Rachel Tate uptoTate ( View Tweet)
Which Axial SpA outcome score do you use in clinic as a target to achieve? @RheumNow #ACR20

Dr. Antoni Chan synovialjoints ( View Tweet)

In SpA-paz cohort 80% of axSpA pts achieved R or LDA at one visit, but only 40% maintained this level of disease control. #ABS0893 #ACR20 @RheumNow https://t.co/3MKBKOoNSw https://t.co/pTMJhtfKbU

Links:

Dr. Rachel Tate uptoTate ( View Tweet)
CZP tx in axSpA pts showed significant reduction of 82% in the AAU flare rate and MSK symptoms over 96 week C-VIEW trial. #ABS0881 #ACR20 @RheumNow https://t.co/bNFHXbKEuF https://t.co/3Z232vKGPC

Links:

Dr. Rachel Tate uptoTate ( View Tweet)
SKIPPAIN trial: SEC showed rapid and significant improvement of spinal pain (primary endpt) and ⬇ disease activity in axSpA @RheumNow #ACR20 abs0899 #ACRbest https://t.co/fKSEjwd6i9
sheila RHEUMarampa ( View Tweet)
Do you consistently address T2T in your axSpA patients in your clinical practice? List your measures below! #ACR20 @RheumNow

Dr. Rachel Tate uptoTate ( View Tweet)

T2T in clinical practice: Most axSpA pts had ≥1 annual ASDAS recorded, but target ID/LDA achieved in only 1/3 of pts at the first measurement. How do you address T2T in your practice? #ABS0879 #ACR20 @RheumNow https://t.co/Jy0mmqpHAb https://t.co/06fI10V3OZ

Links:

Dr. Rachel Tate uptoTate ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×